JNJ - Johnson & Johnson
One of the world's most diversified healthcare companies, spanning prescription pharmaceuticals, medical technology, and a legacy consumer brands portfolio.
Finlify Score
50.2 / 100
Data Quality
FULL
Penalty
0.0
Sector
Health Care
Close Price
$235.66
-2.16%
52W Range
$149.04 - $251.71
Market Cap
$542.4B
-2.2%Compared to previous day
2026 Q1 Revenue
$24.1B
-2.0%Changes from last reporting quarter
2026 Q1 EPS
$2.14
Diluted shares
Analyst Rating
31 analysts in latest ratings feed
RSI
58.0
40-70 moderate
2Y Range Position
86%
-6.4% from high / +67.5% from low
Beta
0.24
Relative to market benchmark
MACD
1.29
MACD line 2.13 / signal line 0.84
Fundamental Trend
Growth 33.1Financial Health
Quality 75.7Data Quality
FULLValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
HOLD50.2 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $24.1B-2.0% | $24.6B+2.4% | $24.0B+1.1% | $23.7B+8.5% |
| Gross Profit | $16.0B-3.9% | $16.6B-0.6% | $16.7B+3.6% | $16.1B+10.9% |
| Operating Income | - | - | - | - |
| Net Income | $5.2B+2.3% | $5.1B-0.7% | $5.2B-7.0% | $5.5B-49.7% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Jun 16, 2026
The Finlify signal for JNJ is a HOLD, with an overall Finlify Score of 53.4 out of 100. This suggests a balanced outlook, where some positive indicators are offset by areas of potential concern.
Technical
Technically, JNJ appears to exhibit strong Relative Strength at 70.0/100, alongside positive short-term momentum with a 20-day return of 4.4% and a 60-day return of 1.5%. The asset is also relatively close to its 52-week high, at -3.1% distance. However, the Accumulation / Volume score of 24.6/100 indicates weaker buying interest, which may temper the overall technical strength, and the RSI(14) at 66.1 suggests the asset is approaching overbought conditions.
Fundamentals
From a fundamental perspective, JNJ demonstrates strong Financial Quality with a score of 75.7/100, indicating robust financial health as of the latest financial period ending 2026-03-29. However, the Fundamental Trend score of 33.1/100 suggests some potential headwinds or slowing momentum in its core business, despite meeting its latest earnings. Valuation metrics, such as a P/E ratio of 21.6x, P/B of 6.1x, and P/S of 6.1x, appear somewhat elevated, while its low Beta of 0.2 suggests lower volatility and a defensive characteristic, complemented by a 2.25% dividend yield.
Macro Context
In the current macro environment, with CPI YoY at 4.3% and Core CPI at 3.0%, JNJ's defensive nature and low Beta of 0.2 may offer some stability amidst elevated inflation and a 10Y Treasury Yield of 4.5%. The positive yield spread of 0.4% (10Y-2Y) suggests a normalized yield curve, which could be generally supportive for the broader market.
Key Risks
- Weak Accumulation / Volume: The score of 24.6/100 suggests limited buying interest, potentially indicating a lack of conviction in recent price movements.
- Weak Fundamental Trend: A score of 33.1/100 may indicate challenges in the company's underlying business momentum or growth prospects.
- Elevated Valuation Metrics: A P/E of 21.6x, P/B of 6.1x, and P/S of 6.1x appear somewhat high, which could limit future upside potential.